Natural CD4+ T-cell responses against Trypanosoma cruzi KMP-11 protein in chronic chagasic patients (Immunology and Cell Biology (2008) DOI: 10.1038/icb.2008.76);Natural CD4+ T-cell responses against Trypanosoma cruzi KMP-11 protein in chronic chagasic patients

Immunology and Cell Biology

Volumn 87, Issue 2, 2009, Pages 149-153

  Cuellar, Adriana ^a   Rojas, Francia ^a   Bolãos, Natalia ^b   Diez, Hugo ^a   Del Carmen Thomas, María ^c   Rosas, Fernando ^d   Velasco, Victor ^d   López, Manuel Carlos ^c   González, John Mario ^b   Puerta, Concepción ^a,e  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b UNIVERSIDAD DE LOS ANDES   (Colombia)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^d Fundacion Clinica Abood Shaio   (Colombia)

^e Grupo de Biotecnología Ambiental e Industrial GBAI   (Colombia)

Author keywords

CD4+ T lymphocytes; Chagas disease; Immune response; Trypanosoma cruzi

Indexed keywords

EPITOPE; GAMMA INTERFERON; KINETOPLASTID MEMBRANE PROTEIN 11; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CHAGAS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DONOR; FEMALE; HEART DISEASE; HELPER CELL; HUMAN; HUMAN CELL; MALE; PROTEIN ANALYSIS; PROTEIN PROCESSING; TRYPANOSOMA CRUZI;

KINETOPLASTIDA; MUS; TRYPANOSOMA CRUZI;

EID: 60749132488     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2008.92     Document Type: Erratum

References (36)

1. Organización Mundial de la Salud. Reporte sobre la enfermedad de Chagas. Grupo de Trabajo Científico. OMS: F. Guhl y J. Lazdins-Helds eds., Argentina, 2007, pp 2.
2. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003; 98: 577-591.
3. Higuchi ML, Benvenuti LA, Martins RM, Metzger M. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res 2003; 60: 96-107.
4. Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M. Chagas' disease. Clin Microbiol Rev 1992; 5: 400-419.
5. Jensen AT, Gasim S, Ismail A, Gaafar A, Kurtzhals JA, Kemp M et al. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kineto-plastid membrane protein-11. Scand J Immunol 1998; 48: 103-109.
6. Marañon C, Thomas MC, Planelles L, Lopez MC. The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes. Mol Immunol 2001; 38: 279-287.
7. Mukhopadhyay S, Sen P, Bhattacharyya S, Majumdar S, Roy S. Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis. Vaccine 1999; 17: 291-300.
8. Planelles L, Thomas MC, Alonso C, Lopez MC. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 2001; 69: 6558-6563.
9. Ramirez JR, Gilchrist K, Robledo S, Sepulveda JC, Moll H, Soldati D et al. Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice. Vaccine 2001; 20: 455-461.
10. Thomas MC, Longobardo MV, Carmelo E, Marañon C, Planelles L, Patarroyo ME et al. Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera. Clin Exp Immunol 2001; 123: 465-471.
11. Diez H, Lopez MC, Del Carmen TM, Guzman F, Rosas F, Velazco V et al. Evaluation of IFN-gamma production by CD8 T lymphocytes in response to the K1 peptide from KMP-11 protein in patients infected with Trypanosoma cruzi. Parasite Immunol 2006; 28: 101-105.
12. Savino W, Villa-Verde DM, Mendes-da-Cruz DA, Silva-Monteiro E, Perez AR, Aoki MP et al. Cytokines and cell adhesion receptors in the regulation of immunity to Trypanosoma cruzi. Cytokine Growth Factor Rev 2007; 18: 107-124.
13. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol 1985; 45: 249-256.
14. + cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun 2006; 74: 2477-2481.
15. + T cells differentiation and proliferation by the timing of increase in the pathogen load. PLoS ONE 2007; 2: e393.
16. + T-cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006; 2: e77.
17. + T cells. Infect Immun 2007; 75: 231-235.
18. Tarleton RL, Grusby MJ, Zhang L. Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi. J Immunol 2000; 165: 1520-1525.
19. + lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection. Cell Immunol 1996; 170: 41-53.
20. Kumar S, Tarleton RL. Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice. J Immunol 2001; 166: 4596-4603.
21. Reyes JL, Terrazas LI, Espinoza B, Cruz-Robles D, Soto V, Rivera-Montoya I et al. Macrophage migration inhibitory factor contributes to host defense against acute Trypanosoma cruzi infection. Infect Immun 2006; 74: 3170-3179.
22. Mussalem JS, Vasconcelos JR, Squaiella CC, Ananias RZ, Braga EG, Rodrigues MM et al. Adjuvant effect of the Propionibacterium acnes and its purified soluble polysaccharide on the immunization with plasmidial DNA containing a Trypanosoma cruzi gene. Microbiol Immunol 2006; 50: 253-263.
23. Hoft DF, Eickhoff CS. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges. Infect Immun 2002; 70: 6715-6725.
24. Guinazu N, Pellegrini A, Giordanengo L, Aoki MP, Rivarola HW, Cano R et al. Immune response to a major Trypanosoma cruzi antigen, cruzipain, is differentially modulated in C57BL/6 and BALB/c mice. Microbes Infect 2004; 6: 1250-1258.
25. Laucella SA, Postan M, Martin D, Hubby FB, Albareda MC, Alvarez MG et al. Frequency of interferon-gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 2004; 189: 909-918.
26. Hermann E, Truyens C, Alonso-Vega C, Rodriguez P, Berthe A, Torrico F et al. Congenital transmission of Trypanosoma cruzi is associated with maternal enhanced parasitemia and decreased production of interferon-gamma in response to parasite antigens. J Infect Dis 2004; 189: 1274-1281.
27. Dutra WO, Martins-Filho OA, Cancado JR, Pinto-Dias JC, Brener Z, Freeman Junior GL et al. Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. Int Immunol 1994; 6: 499-506.
28. + T cell death by apoptosis in experimental Chagas' disease. J Immunol 1995; 154: 744-752.
29. Kahn SJ, Wleklinski M. The surface glycoproteins of Trypanosoma cruzi encode a superfamily of variant T cell epitopes. J Immunol 1997; 159: 4444-4451.
30. Sztein MB, Cuna WR, Kierszenbaum F. Trypanosoma cruzi inhibits the expression of CD3, CD4, CD8, and IL-2R by mitogen-activated helper and cytotoxic human lymphocytes. J Immunol 1990; 144: 3558-3562.
31. + parasite-specific T-cells by macrophages infected with live T. cruzi amastigotes. Immunol Lett 1998; 63: 97-105.
32. Arnholdt AC, Piuvezam MR, Russo DM, Lima AP, Pedrosa RC, Reed SG et al. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase. J Immunol 1993; 151: 3171-3179.
33. Martin DL, Tarleton RL. Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol 2005; 174: 1594-1601.
34. Souza PE, Rocha MO, Menezes CA, Coelho JS, Chaves AC, Gollob KJ et al. Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease. Infect Immun 2007; 75: 1886-1894.
35. World Health Organization. Control of Chagas Disease. Second report of the WHO Expert Committee, Technical Report 2002. WHO: Geneva, 2002, series 905: pp 24-28.
36. Jaimes MC, Rojas OL, Gonzalez AM, Cajiao I, Charpilienne A, Pothier P et al. Frequencies of virus-specific CD4(+) and CD8(+) T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol 2002; 76: 4741-4749.